Transcript FP 6 Presentation

PRIORITY 1
Life sciences, genomics and biotechnology
for health
From Expressions of Interest to a
Workprogramme for 2003
Slide 1
FP6 - Expressions of Interest - Response
Priority theme 1:
Life Sciences, Genomics & Biotechnology for Health
IPs
NoEs
Unspecified
Total
288
190
45
523
Applied genomics & biotech 240
125
36
401
Major diseases
459
219
24
702
Cancer
196
102
4
302
41
28
-
1224
664
109
Fundamental genomics
Poverty related diseases
Total
17% of EoIs for all 7 priority themes
Slide 2
69
1997
FP6 - Expressions of Interest - Theme 1
Distribution of EOIs - by type of
submitting institution
4%
6%
Higher
Education
Research
Institute
25%
Industry
65%
Other
Slide 3
FP6 - Expressions of Interest - Theme 1
Industry, including SME, involvement (% submitters)
4% overall
8% Fundamental knowledge and basic tools
10% Applications of knowledge and technologies...
N.B 15% of budget for SMEs
Gender balance (% submitters)
16% female
84% male
Slide 4
EoIs- countries of submitters - Theme 1
350
300
250
200
150
100
50
No. of EoIs per country of submitter (n)
10 % from candidate countries
Slide 5
No. of EoIs
UK
O
th
er
SK
Sl
SE
RO
PT
PL
NO
NL
T
M
LT
IT
IS
IL
IE
HU
G
R
FR
FI
ES
EE
DK
DE
CZ
CY
CH
BG
BE
AT
0
FP6 - Expressions of Interest - Theme 1
Outcome of the panel meeting
Categories of scientific topics - all panels
 1. Strategic importance for Europe & thematic
priority; ready for implementation through an IP or NoE
 2. Not-relevant to the thematic priority;
less obvious strategic importance for Europe
Some panels
 3. Strategic importance for Europe & thematic
priority; BUT not yet mature for an IP or NoE (based on
the EoIs received)
 4. Strategic importance but not covered by any
EoIs or the EoIs were not well argued
Slide 6
FP6 - Expressions of Interest - Theme 1
Analysis Methodology
At the panel meeting in Bussels
“Citation list” of EoIs
 to start the discussion
- cited EoIs
- non-cited EoIs
- expert rapporteur for every EoI
Some EoIs analysed by more than one panel (broad
scope)
Definition of topics for IP and NoE
- no pre-selection of particular EoI or consortium
Slide 7
Fundamental knowledge and basic tools
for functional genomics in all organisms
• In total, 30 recommended topics
• 15 topics will be published in first call; 15 in second call
• The selected topics will be open only for the call
indicated
• It is envisaged that no more than 1 project utilising a
new instrument will be funded for each topic
• There will be competition between topics as well as
within topic areas
• This will result in some topic areas not being supported
Slide 8
Gene expression and Proteomics
Examples
• Advanced array technologies
• High throughput proteomics
for large data set of proteinprotein interactions
• In situ gene expression
analysis in mouse and
human tissues
Structural genomics
Examples
• Viral replication
• Membrane proteins
• Supramolecular analysis (NoE) • Large protein complexes
• Hardware and software for
automated technologies at
synchrotron sites (IP)
Slide 9
Comparative genomics & Population genetics
Examples
• Non-mammalian
vertebrate models
(IP)
• In-vivo imaging for
phenotyping and
functional analysis
• RNA interference screening in
Arabidopsis for processes relevant
to health
• Phenotyping human populations
• Bacterial diversity with relevance to
human health (NoE)
• High throughput genotyping in
human populations (NoE)
Bioinformatics
Examples
• Annotation of
human and other
genomes (NoE)
Slide 10
• Genomics grid for European
research (NoE)
• Software platform to tackle
sequence-structure-function
relationships
Basic biological processes
Examples:
• Cell cycle
• Kidney disease
• Non-human embryonic stem
• Peroxisomes
cell differentiation
• Erythroid development (IP)
• Lymphangiogenesis
• Inflammation processes (NoE)
• Ubiquitin-proteasome (NoE)
• Epigenetics (NoE)
Slide 11
• Inner ear or retina
development
• DNA damage and repair
• Disease of the immune
system or of the muscle
• X-linked syndromes
Traditional instruments
Examples:
• Transcription activation
• Signal transduction
• Intracellular communication
• Non-coding genomic information
• Integration of genes
• In silico prediction of gene function
• Simulation of complex regulatory networks
• New tools and approaches, standard protocols producing
knowledge in functional and structural genomics
Slide 12
Applications of knowledge and technologies in
the field of genomics and biotechnology for health
Strategic Objective:
To foster the competitiveness of Europe’s
biotechnology industry by exploiting the wealth of
biological data produced by genomics and advances
in biotechnology
Slide 13
Applications of knowledge and technologies in
the field of genomics and biotechnology for health
Development of Technological Platforms
• Industry
• SME
• Academics
• Stakeholders
Civil society
Slide 14
TECHNOLOGICAL
PLATFORMS
Integrated
Multidisciplinary
Research
EU project
- Health care progress
- Increased quality of life
- Cost reduction
- Precise diagnostics
- Individualised treatments
- New drugs and therapies
- Novel products from genomics
and biotechnology
Deliverables
Applications of knowledge and technologies in
the field of genomics and biotechnology for health
Technology Platforms will focus their research activities on:
• New, safer and more effective drugs including
pharmacogenomics approaches
• New diagnostics
• New in vitro tests to replace animal experimentation
• New preventive and therapeutic tools such as somatic gene
and cell therapies (in particular stem cell therapies) and
immunotherapies
• Innovative research in post-genomics (novel products from
genomics and biotechnology)
Slide 15
STEM CELL Therapies
• Detailed implementing provisions concerning research
activities involving the use of human embryos and
human embryonic stem cells which may be funded
under the 6th Framework Programme shall be
established by 31 December 2003.
• During that period and pending establishment of the
detailed implementing provision, the Commission will
not propose to fund such research, with the exception
of the study of banked or isolated human embryonic
stem cells in culture.
Slide 16
New, safer and more effective drugs including
pharmacogenomics approaches
Examples
•
•
•
•
Drugs for aberrant molecular
signalling in protein phosphorylation
pathways (IP)
Genome-based individualised
medicine
Drugs for psychiatric disorders (NoE)
Antiviral therapies (IP)
•
Medicines for paediatrics
•
Computer-assisted modelling for
drugs
•
Therapeutics for neurodegenerative
diseases
Development of new diagnostics
Examples
•
•
Non-invasive diagnostics:
Development of markets for anteand neonatal screening (NoE)
•
Genetic tests allowing for
harmonisation, validation and
standardisation
In-vivo molecular imaging
Development of new in vitro tests
Examples
•
Combined in vitro cell and sensor
technologies for animal toxicology (IP)
Slide 17
•
Test batteries for human acute
toxicity
New preventive and therapeutic tools
Examples
•
•
•
New cell lines for cellbased therapies (IP)
•
Gene delivery systems against severe acquired
diseases
•
Gene therapy of inherited diseases
Allogenic stem cell
•
transplantation for
haematological and
neoplastic diseases (IP) •
Safety, quality, standardisation of stem cells
(European registry)
Cell-based therapies for •
regeneration of
connective tissue (IP)
•
Vaccine delivery systems (bacterial, synthetic, aimed
at dendritic cells, etc…)
Regeneration therapies for vital organs
New chemokine modulators in autoimmune diseases
Innovative research in Post-Genomics
Examples
•
•
Post-genomic approaches against
asthma and autoimmune diseases (IP)
Plant platforms for immunotherapeutic
biomolecule production (IP)
Slide 18
•
RNA as human therapeutic tool
•
Post-genomic approaches to study
human pathogens
Pre-clinical and clinical applications
•
New, safer and more effective drugs including
pharmacogenomics approaches
Examples:
Blood substitutes (e.g. oxygen carriers), G-Protein coupled receptors
Development of new diagnostics
Examples:
Non-invasive diagnostics using bioinformatics tools,
Diagnostics for prion diseases
Development of new in vitro tests
Examples:
Competitive product screening & development process
stages lead compounds by introduction of alternative testing
New preventive and therapeutic tools
Examples:
Vaccine technologies targeted to dendritic cells
Databank on immuno therapies, comprising advances from
genomics, proteomics and cell biology
Stem cell products for myocardial repair
Innovative research in post-genomics
Examples:
Slide 19
Combinatorial biosynthesis, Optically-active therapeutic
biomolecules by biocatalysis, Precision technology platforms
from post-genomics
Combating major diseases
Fields of research:
• Combating cardiovascular diseases,
diabetes and rare diseases
• Combating resistance to antibiotics and
other drugs
• Studying the brain and combating
diseases of the nervous system
• Studying human development and the
ageing process
TOTAL
• Cancer
Slide 20
Number of EoIs:
286
77
281
58
702
58
Combating cardiovascular disease,
diabetes and rare diseases
Examples:
• Molecular targets in obesity from
diabetes
• Coronary Artery Disease
• Genomics of heart muscle
development (NoE)
• Genomics of vascular disease
(NoE)
• Pancreatic ion channels in type II
diabetes (IP)
• Rare disorders of mitochondria
• Hypertension
• Genomics of type II
diabetes
• Exercise and
metabolic syndrome
• Eicosanoids and
nitric oxide as
mediators of
diseases
• Rare disorders of plasma membrane transporters
N° of EoIs: 286
Slide 21
Combating resistance to antibiotics and
other drugs
Examples:
• Upper Respiratory Tract
Infections (NoE)
• Anti-viral drug resistance
• Antibiotics producing
organisms
• New targets for drugs - the
ribosome
• Anti-fungal resistance
• Microbial ecology epidemiology
• Control of hospital acquired
infections
• Broadening the knowledge base on molecular mechanisms
behind resistance
• Non antimicrobial therapies
Slide 22
Studying the brain and combating
diseases of the nervous system
Examples:
•
•
•
•
Protein aggregation
Eating disorders (IP)
Bipolar disorders (IP)
Rare neurological diseases:
ataxias
• Brain development,
degeneration and regeneration
(NoE)
• Brain tissue research (NoE)
• Addiction
• Cortical processing:
learning, memory,
behavior
• Cortical development
• Stem cells and
nervous system
• Rare monogenic neurological disorders, Genetics and
neurobiology of pain, Schizophrenia
Slide 23
N° of EoIs: 281
Human Development and Ageing
Examples:
• Longevity
• Mesodermal organ system
(NoE)
• Mitochondrial
dysfunction
• Embryo implantation
• Congenital anomalies
Markers
• Aberrant Steroid
signalling
• Biochemistry of Reactive Oxygen Species
• Molecular mechanisms of bone homeostasis
N° of EoIs: 58
Slide 24
Cancer
Selected 6 out of 14 topics for first call in order to ensure:
 Potential co-ordination of complementary areas (e.g.
molecular targets - molecular imaging)
 Balanced coverage of the main WP areas:
A. Establishing facilities for exploitation of research
• Registries and repositories
B. Clinical research
• European networks for clinical trials
• Molecular imaging for early detection
• Radiation therapy
C. Translational research
• Functional oncogenomics
• Molecular targets
Slide 25
Overall Research Strategy of the 6th Framework Programme
to confront HIV/AIDS, Malaria and Tuberculosis
EUROPEAN DEVELOPING COUNTRIES
CLINICAL TRIALS PARTNERSHIP (EDCTP)
HIV/AIDS
Malaria
Clinical Trials
(Phase II/III)
TB
Phase I trials
NEW INSTRUMENTS
• Vaccines
• Vaccines
• Microbicides
• Therapy Trials
in Europe
• Biology and
Pathology
(NoE)
• Drugs
Pre-clinical
•Vaccines
•Drugs
CROSS-CUTTING TOPICS:
Mucosal vaccines for PRD
Neonatal vaccination strategies for PRD
H I G H R I S K P R O J E C T S ( S T R E P)
Slide 26
Discovery
Genomics
Confronting the major communicable
diseases linked to poverty
Fields of research
Tuberculosis
Malaria
HIV
Horizontal topics covering
the three diseases
1
Not relevant
TOTAL
Number of EoIs
13
17
22
11
6
69
High level of interest, excellent quality of the EoI: most EU
leading researchers represented in one or more EoI
Slide 27
EoI’s Panel main recommendations
• Encourage participation of partners from DC
• Stimulate the training component both for the North
and the South
• Increase the professionalism of management
• Include in the projects pre-clinical testing in non-
human primates and GMP production of candidate
drugs or vaccines
Slide 28
PRIORITY 5
Food Quality & Safety
From Expressions of Interest to a
Workprogramme for 2003
Slide 29
Response to invitation to submit Expressions of
Interest for priority 5
eoi
43%
EOI
33%
41%
Not indicated
industrial
Integrated project
public
Network of excellence
educational
51%
24%
Type of instrument
Type of submitter
23%
MALE
FEMALE
77%
Gender of submitter
Slide 30
8%
Expert comments on nonselected EoI
• Very many EOIs on similar subjects
• Many were technical skills looking for funds
• Many were on a very large scale with little indication of
management skills
• Need for a “Development Bank” business plan approach
• Lack of analysis on the importance of the problems to be
addressed and of any potential benefits
• No gender balance awareness
• IP management was weak
• No gender balance awareness and IP management was weak
Slide 31
From EoI to Workprogramme
• Budget: 149 M€ in 2003
• Focussing: from 53 topics through EoIs down to ...
• Consultation of AG and committee
• Maturity of the topic
• Readiness of the topics for new instruments or
traditional instruments
• Urgency of the issue: 2003 or 2004
Slide 32
Format of the Draft Workprogramme (1)
• Common format for all Thematic Priorities
• Follows the specific programme
• Introduction to each area: clear signals
• NI (NE/ IP) or TI (STREP/ CA)
Slide 33
Format of the Draft Workprogramme (2)
• 2003:
- selected topics
- detailed description
(objectives/disciplines/expected outcome)
• 2004:
- indicative areas
- outline description
• Objectives for Specific Support Measures
Slide 34
A likely (but non-binding) scenario
Area
Total food chain
Epidemiology of food-related diseases and
allergies
Impact of food on health
Traceability processes along the food chain
Methods of analysis, detection and control
Safer and environmentally production methods
Impact of animal feed on human health
Environmental health risk
Total
Slide 35
2003
NI
TI
2
1
1
1
2004
NI
TI
1
0
2
1
2
1
2
3
1
2
14
4
0
2
3
0
2
14
1
0
1
4
1
2
11
0
0
1
5
0
2
9
Total Food Chain
Examples:
 Food from low input and organic production systems:
Ensuring the safety and improving quality along the whole
chain
 Quality seafood for improved consumer health and wellbeing
 Improving the quality and safety of beef for the consumer
 Pathogen free production systems
Slide 36
Epidemiology of food-related diseases and allergies
Examples:
 Validated food information database for Europe (NoE)
 Epidemiology of food allergy
 Influence of gene-nutrient interaction on the development of
chronic diseases
 Influence of nutrition and lifestyle on healthy ageing aimed at
preventing adult degenerative disease
 Nutritional and lifestyle habits of adolescents throughout Europe,
including production of functional foods with sensory properties
attractive to adolescents
Slide 37
Impact of food on health
Examples:
 Functional genomics in relation to food, nutrition and health
(NoE)
 Lipid metabolism and the metabolic syndrome
 Food safety, risk assessment and communication
 Programming effects of early nutrition on long-term health
 Microbes, the immune system and gut health
 Improving and enhancing the nutritional value and health
benefits of cereals
 Health risks from heat-treated foods and food products
Slide 38
“Traceability” processes
along the production chain
 Development of reliable traceability methods and systems
to establish the origin/mode of productin of food products
Slide 39
Methods of analysis, detection and control
Examples:




Zoonoses including food borne diseases (NoE)
Prion diseases (NoE)
Chemical contaminants in food products
Emerging and future food borne pathogenic microorganisms
throughout the food chain
 Quantitative risk assessment strategies based on
probabilistic, genomic and profiling approaches including a
risk-benefit analysis for novel foods
 Cost-effective tools for risk management and traceability
systems for zoonotic agents and phycotoxins in seafood
Slide 40
Safer and environmentally friendly production
methods and healthier foodstuffs
Examples:












High throughput analysis of plant
composition and metabolism for
optimising end-product quality
Animal welfare for improved food
quality
Genomics of host-pathogen
interactions in animals (NoE)



Soil microbial community
management for safe production
under stress conditions
Plant biodiversity to reduce pesticide
application
Immunological basis for protection
against animal disease
Antibiotic resistance
Crop protection systems based on biological control agents and semiochemicals
Modelling of improved crop establishment in low input systems
Plant flavonoids
Recycled organic wastes from the food chain
Sustainable aquaculture
GMO co-existence analysis
Use of genetic resistance to control plant viruses
Disease risk from alternative and enriched cage and free-range systems
Slide 41
Impact of animal feed on human health
 New strategies to improve grain legumes for food
and feed
 Alternatives to antimicrobials in feeds
Slide 42
Environmental health risks
Examples:




Allergy and asthma network
Exposure to chemical residues in the environment
Environmental factors and puberty onset
Cancer risk from environment, diet and genetic




Human pathogens in drinking water
Food and fertility
Neurotoxic effects of environmental contamineants
Exposure to complex chemical mixtures
Slide 43